Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2018 07:00 ET | Source: ObsEva SA

ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA...
April 16, 2018 07:00 ET | Source: ObsEva SA

ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
March 26, 2018 07:00 ET | Source: ObsEva SA

ObsEva SA to Participate in the H.C. Wainwright Annual Global Life Sciences Conference April 8-10, 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
March 09, 2018 08:46 ET | Source: ObsEva SA

ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Pipeline Achievements in 2017 Included...
March 09, 2018 07:00 ET | Source: ObsEva SA

ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Pipeline Achievements in 2017 Included...
March 02, 2018 07:00 ET | Source: ObsEva SA

ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
March 01, 2018 07:00 ET | Source: ObsEva SA

ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Oral administration of OBE022 shows...
February 26, 2018 07:00 ET | Source: ObsEva SA

ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} The WHO considers infertility a global...
February 23, 2018 16:00 ET | Source: ObsEva SA

ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
February 07, 2018 07:00 ET | Source: ObsEva SA

ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...